Clinical trials, biomarkers, microbiome, genetics, AI, basic science, and emerging IBD research.
Page 10 of 65 · 3080 articles
This study helps pinpoint which gut cell types and regulatory DNA regions are most likely to mediate genetic risk for Crohn’s disease, which can guide future research toward relevant cells and pathways.
If validated, early bedside ultrasound changes could let clinicians identify within days whether steroids or biologics are working, enabling faster treatment adjustments and potentially avoiding prolonged ineffective...
Families and clinicians deciding on a first biologic for a child with ulcerative colitis need to know which drugs have pediatric-specific evidence. This review shows infliximab has the strongest pediatric data, while...
People with IBD or their clinicians may see signals suggesting certain drugs are more often reported with ulcerative colitis; this study combines adverse‑event reports with gene‑expression comparisons to help prioritize...
Researchers exploring new anti-inflammatory or metabolism-targeting approaches for UC might view KA as a candidate molecule that modulates arginine–polyamine metabolism, which could point to new drug-discovery...
If local norepinephrine promotes neutrophil‑driven inflammation in UC, that could help explain disease progression in some patients and point to biomarkers (ADRB2‑rich neutrophils) that might predict response to anti‑TNF...
STAT3 is a central immune signaling molecule implicated in ulcerative colitis; understanding its dual roles could influence future biomarker research and therapies for UC. The review highlights why STAT3’s...
Researchers are exploring whether ketone metabolism or ketogenic diets could affect inflammation, barrier function, and the microbiome — all central to IBD. Patients may see interest because dietary approaches and...
If you or your child is starting exclusive enteral nutrition (EEN) for pediatric Crohn’s disease, this review explains why outcomes vary and what tests and research might help predict who will benefit.
This work organizes preclinical evidence connecting Atractylodes macrocephala constituents to intestinal barrier protection, immune modulation, and microbiota changes relevant to ulcerative colitis—useful for researchers...
Up to one-third of people with IBD in clinical remission still have IBS-like symptoms that reduce quality of life and are not helped by anti-inflammatory treatments.
Cure8 found this source from technology.org, but the page could not be read reliably yet. It is tagged for Research and clinical trials. Open the original article for the full details.
Patients with fibrostenosing Crohn’s disease face progressive strictures and limited targeted treatments; data from STENOVA’s OLE and the planned NOV‑ERA trial could advance therapies that target both inflammation and...
If confirmed, a pretreatment mucosal JAK‑dependent inflammatory signature could help predict who will respond to tofacitinib, potentially guiding therapy choice and avoiding ineffective treatment for people with...
Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease and Research and clinical trials. The original article is from Internal medicine journal.
Pulmonary nodules appear more frequently in people with Crohn’s disease and have distinct patterns over time. Knowing which factors predict nodule burden can help clinicians prioritize monitoring and interpret chest...
Rising IBD incidence and prevalence in Asia mean more people will need long-term care, specialist services, and health-system planning. Understanding regional trends helps patients and policymakers anticipate resource...
Cure8 found this source from tipranks.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original article for the...
The study identifies an epithelial cell death signature (necroptosis then apoptosis) that appears before major inflammation and which correlated with relapse over 24–36 months, suggesting a possible early biomarker to...
Extraintestinal problems are common in IBD and can cause significant symptoms and treatment needs beyond the bowel. Knowing their frequency helps patients and clinicians prioritize screening and multidisciplinary care.
A platform trial could evaluate multiple advanced therapies and combinations more efficiently, which matters for people with refractory Crohn's disease who have already tried several advanced treatments.
Digital momentary symptom and food-tracking could help people with IBS or IBD-IBS identify personal triggers and tailor lifestyle or treatment choices, potentially reducing abdominal pain and improving quality of life.
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Journal of inflammation...
People with UC often try complementary therapies; this review shows that benefits and risks vary by specific CHM product and that current evidence is mixed and product-dependent.
Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease, Microbiome, and Research and clinical trials. The original article is from Frontiers in cellular and...
A new chemiluminescent probe could help researchers see and measure MPO-driven HOCl inflammation deeper in tissues, which may speed preclinical testing of IBD therapies and biomarker development.
People with IBD often have sleep problems and ongoing inflammation; melatonin could help both sleep and clinical disease activity, which may improve quality of life. The review suggests potential benefit but is not...
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Microbiome. The original article is from Folia Microbiologica.
If findings translate beyond mice, exposure to titanium dioxide during pregnancy could influence offspring gut barrier, microbiota, and susceptibility to inflammatory colitis — a potential public-health concern for...
If true, the tripartite circuit model helps explain why some patients respond to therapies that target one pathway while others do not — because other nodes in the loop may sustain disease.
Identifying people at very early, preclinical stages of Crohn’s disease could allow enrollment in prevention trials and earlier intervention. Faecal calprotectin may help select higher‑risk first‑degree relatives for...
Detecting molecular signs of IBD before symptoms could eventually allow earlier monitoring or preventive strategies, changing how and when people at risk are identified. For patients, this research points to hope that...
This study gives real-world comparative data on two biologic options (vedolizumab vs anti-TNFα) used early in the treatment course for Crohn’s disease, which may help patients and clinicians weigh effectiveness and...
Based on the title and source metadata, this appears to be a case report related to Inflammatory bowel disease and Research and clinical trials. The original article is from Journal of the Formosan Medical Association =...
A subcutaneous option for infliximab could simplify maintenance therapy, reduce infusion visits, and change how drug levels and accompanying immunomodulators are managed — issues many people with IBD and their clinicians...
Patients and clinicians choosing among advanced therapies for ulcerative colitis may consider infection-related hospitalization risk as one factor; this study suggests lower risk with ustekinumab versus TNF antagonists...
The study suggests habitual diet that supports gut microbes may modestly lower the chance of developing IBD, especially ulcerative colitis, and links dietary patterns to blood protein changes tied to immune and...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Infliximab. The original article is from Inflammatory Bowel Diseases.
Predicting who will relapse after stopping anti-TNF drugs could help avoid unnecessary flares or unnecessary ongoing treatment. A biopsy-based transcriptomic test could be a useful decision tool if validated.
The work suggests MSC-derived exosomes may reduce colitis and alter the gut microbiome and metabolites (notably SCFAs) in ways linked to lower inflammation, which could inspire future therapeutic research for IBD.
The paper points to S100A8 as a potential link between immune-cell-driven inflammation and mitochondrial stress in Crohn’s disease, which could help researchers explore new biomarkers or targets for study.
Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease and Research and clinical trials. The original article is from The New England journal of medicine.
The study connects microbiome disruptions to new food intolerances in people with IBD in remission, which may explain persistent food-related symptoms despite controlled inflammation and could point to microbiome-based...
If you have ulcerative colitis, this preclinical study suggests high‑fat diets may worsen intestinal inflammation through metabolic and mitochondrial pathways that impair the gut barrier. Targeting the AMPK/PPARα pathway...
Based on the title and source metadata, this appears to be a basic science related to Inflammatory bowel disease and Research and clinical trials. The original article is from Nature Communications.
This study proposes three autophagy-related genes (APOL1, CCL2, IL24) as potential biomarkers that may help classify ulcerative colitis patients into subtypes with different immune environments, which could eventually...
This preclinical study suggests raising mesaconate in the gut can reduce inflammation in mouse models of Crohn’s disease, using either an engineered probiotic or a zinc–mesaconate formulation—approaches that could...
Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease and Research and clinical trials. The original article is from International journal of nanomedicine.
